SCHEMBL5369914

SCHEMBL5369914

COCCc1nc2cnc3ccccc3c2n1CCCCCSC

nearest known ligand 0.39

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.39
TLR7 Q9NYK1 14/20 0.39
TLR8 Q9NR97 1/20 0.37
TSHR P16473 1/20 0.36
PDE10A Q9Y233 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5356205 0.87 TLR7 (0.50) TLR7TLR8TSHRLMNA
SCHEMBL20796917 0.87 SMN1; SMN2 (0.42) SMN1; SMN2TLR7TLR8TSHRPDE10A
SCHEMBL5361275 0.86 TLR7 (0.53) SMN1; SMN2TLR7TLR8TSHRLMNA
SCHEMBL30851265 0.86 SMN1; SMN2 (0.51) SMN1; SMN2TLR7TLR8TSHRMEN1
Hydrochloric Acid SCHEMBL20796919 0.86 SMN1; SMN2 (0.41) SMN1; SMN2TLR7TLR8TSHRPDE10A
SCHEMBL24414984 0.86 TLR7 (0.51) SMN1; SMN2TLR7TLR8TSHRPDE10A
SCHEMBL20796926 0.86 SMN1; SMN2 (0.51) SMN1; SMN2TLR7TLR8TSHRMEN1
SCHEMBL5359899 0.86 TLR7 (0.41) SMN1; SMN2TLR7TLR8TSHRPDE10A
SCHEMBL5362468 0.84 TLR7 (0.41) SMN1; SMN2TLR7TLR8
SCHEMBL5616985 0.84 TLR7 (0.44) TLR7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288550-B2 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-10-30 US disclosed
US-7276515-B2 Thioether substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-10-02 US disclosed
US-6949649-B2 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO. (US) 2005-09-27 US disclosed
US-20050209267-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2005-09-22 US disclosed
US-20050209268-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2005-09-22 US disclosed
US-6921826-B2 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO. (US) 2005-07-26 US disclosed
EP-1541572-A1 Thioether substituted imidazoquinolines 3M Innovative Properties Company (US) 2005-06-15 EP disclosed
EP-1341791-B1 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2005-05-25 EP disclosed
EP-1451191-A1 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2004-09-01 EP disclosed
US-20040102471-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-05-27 US disclosed
US-20040097736-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-05-20 US disclosed
US-6667312-B2 Useful as immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY 2003-12-23 US disclosed
US-6664264-B2 Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US disclosed
EP-1341791-A2 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-10 EP disclosed
WO-2003050121-A1 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
US-20030100764-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-29 US disclosed
US-20020173655-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
WO-2002046192-A2 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209267-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 SMN1; SMN2 3375/4885TLR7 30/4885TLR8 107/4885
US-20050209268-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 SMN1; SMN2 3375/4885TLR7 30/4885TLR8 107/4885
US-20040097736-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 SMN1; SMN2 3375/4885TLR7 30/4885TLR8 107/4885
US-20020173655-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 SMN1; SMN2 3375/4885TLR7 30/4885TLR8 107/4885
US-20040102471-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 SMN1; SMN2 3375/4885TLR7 30/4885TLR8 107/4885
US-20030100764-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 SMN1; SMN2 3375/4885TLR7 30/4885TLR8 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.